Illumina, Inc. (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays. Illumina also provides software and informatics solutions to support data analysis and workflow management, along with services and support for adoption of genomics in research and clinical settings. Its offerings are designed to address whole-genome, exome, transcriptome and targeted sequencing needs across discovery and diagnostic workflows.
Illumina operates globally, selling products and services across the Americas, Europe, the Middle East, Africa and the Asia-Pacific region. Since its founding, the company has played a central role in lowering the cost and increasing the throughput of DNA sequencing, enabling broader use of genomic tools in research and medicine. Illumina’s strategy emphasizes technological innovation, partnerships and an executive leadership team and board that guide product development, commercial operations and regulatory and market access activities worldwide.
AI Generated. May Contain Errors.
